GlassScriptPhysician profile
Cameren J Hackley
NPI 1285185835
$5,466.78
in general payments reported to CMS, 2019-2025
33 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $937 · 2022: $1,098 · 2023: $1,019 · 2024: $1,367 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,432.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,045.40 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $697.01 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $682.89 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $451.19 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $359.02 | 2021-2025 | |
| Pfizer INC. | $239.39 | 2022-2025 | |
| Amgen INC. | $188.40 | 2021-2025 | Otezla, Repatha, Evenity |
| Abbott Laboratories | $161.39 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $153.56 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $141.78 | 2021-2025 | |
| Dexcom, INC. | $141.68 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $135.76 | 2022 | |
| Nevro Corp. | $113.28 | 2024 | Senza |
| Janssen Pharmaceuticals, INC | $113.16 | 2021-2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.00 | 2025 | Caplyta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $98.03 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $88.32 | 2021 | |
| Astellas Pharma US INC | $82.29 | 2024-2025 | Veozah |
| Amarin Pharma, INC. | $69.87 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.00 | 2022 | |
| Eisai INC. | $41.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.34 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $36.50 | 2025 | Austedo Xr |
| Mylan Specialty L.P. | $30.59 | 2024 | Yupelri |
| Insmed, INC. | $29.81 | 2024-2025 | Brinsupri, Arikayce |
| Phathom Pharmaceuticals, INC. | $27.12 | 2025 | Voquezna |
| Corcept Therapeutics | $24.39 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.55 | 2024 | Rexulti |
| Biocomposites INC | $19.84 | 2025 | Stimulan |
| Almatica Pharma LLC | $17.56 | 2022 | |
| Medtronic, INC. | $16.47 | 2025 | Venaseal |
| Paratek Pharmaceuticals, INC. | $15.58 | 2022 | |
| Merck Sharp & Dohme LLC | $15.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameren Hackley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.